Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS 1/20 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris,Contraceptive for women with menstrual disorders
Prevention of pregnancy
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Both ethinyl estradiol and gestodene are metabolized primarily in the liver via the cytochrome P450 3A4 (CYP3A4) pathway. Ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation; gestodene is hydroxylated and conjugated.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinylestradiol: 98% bound to albumin. Gestodene: 75-90% bound to sex hormone-binding globulin (SHBG) and albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinylestradiol: ~2.4 L/kg. Gestodene: ~0.7 L/kg. Indicates extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Ethinylestradiol ~40-60% (first-pass metabolism). Gestodene ~99% (highly bioavailable due to minimal first-pass effect).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dosage adjustment required for mild-to-moderate renal impairment. Insufficient data for severe renal impairment; use with caution.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in hepatic adenomas, active liver disease, or Child-Pugh class B/C cirrhosis. For mild hepatic impairment (Child-Pugh A), no dosage adjustment; monitor.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use in pediatric patients before menarche. Post-menarche, same as adult dosing; use only after establishment of regular menstrual cycles.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific geriatric dosing; generally not used in elderly women due to increased risk of thromboembolism.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is particularly pronounced in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Risk of thromboembolic disorders (venous and arterial), including myocardial infarction and stroke,Increased risk of hypertension and associated vascular complications,Potential hepatic neoplasia (benign and malignant),Possible exacerbation of cholestatic jaundice or gallbladder disease,May cause fluid retention, which can aggravate conditions such as migraine, asthma, cardiac, or renal dysfunction,Altered carbohydrate metabolism: monitor glucose in diabetic patients,May worsen depression or epilepsy
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Current or history of thrombosis (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke),History of cerebrovascular accident,Current or history of breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Active liver disease or impaired liver function,Hypersensitivity to any component of the product,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) at age ≥35,Major surgery with prolonged immobilization
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions are reported for GILDESS 1/20. However, grapefruit juice may increase estrogen levels; advise patients to consume grapefruit products in moderation. Alcohol may impair judgment regarding missed doses; recommend moderate intake.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction) from estrogen component; cardiovascular and nervous system malformations reported. Second and third trimesters: associated with masculinization of female fetus from progestin; increased risk of IUGR and preterm birth. Use contraindicated in pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk; ethinyl estradiol M/P ratio ~0.4, desogestrel M/P ratio ~0.6. May reduce milk quantity and quality; small amounts pose theoretical risk of estrogenic effects in infant. Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, increased renal clearance) would reduce efficacy, but use is not recommended.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
GILDESS 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. It is indicated for contraception and may be used for acne vulgaris in women at least 15 years old. Monitor for breakthrough bleeding, especially in the first cycles. Counsel patients to take at the same time daily to maintain efficacy. Caution in women with migraine with aura, hypertension, or history of thromboembolism. Prescribe as a 21-day regimen with a 7-day hormone-free interval.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill at the same time every day, even if you do not have sex often.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider.,Use a backup method (like condoms) if you miss more than one pill or start late.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few cycles.,Contact your doctor if you experience severe abdominal pain, chest pain, headache, vision changes, or leg pain/swelling.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking while on this medication.,Do not take GILDESS if you are pregnant or suspect pregnancy.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS 1/20 vs ALYACEN 7/7/7, answered by our medical review team.
GILDESS 1/20 is a Oral Contraceptive that works by GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS 1/20 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS 1/20 is: One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS 1/20 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS 1/20 is classified as Category C. GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.